WAM
AZN icon

Wolverine Asset Management’s AstraZeneca AZN Stock Holding History

Wolverine Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-31,400
Closed -$2.14M – 1336
2017
Q2 		$2.14M Buy
31,400
+28,700
+1,063% +$1.87M 0.03% 425
2017
Q1 		$168K Sell
2,700
-6,600
-71% -$384K ﹤0.01% 878
2016
Q4 		$508K Buy
+9,300
New +$528K 0.01% 671

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Wolverine Asset Management's AZN Position: Q1 2026 in Review

Wolverine Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,872 shares — an estimated $344K sold.

Wolverine Asset Management first reported a position in AZN in Q2 2013 and held it in 40 quarters. The position peaked at $462K in Q3 2013. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Wolverine Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 1,872 AstraZeneca shares in Q1 2026, an estimated $344K.
  • Wolverine Asset Management first reported a position in AstraZeneca in Q2 2013 and held it in 40 quarters.
  • Wolverine Asset Management's AstraZeneca position peaked at $462K in Q3 2013.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.